Exact Mass: 299.0381654
Exact Mass Matches: 299.0381654
Found 62 metabolites which its exact mass value is equals to given mass value 299.0381654,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Creatinine citrate
2-acetamido-3-(2,3-dihydroxybenzoylthio)propanoic acid
Ticlopidine Hydrochloride
C14H15Cl2NS (299.03022100000004)
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents Ticlopidine hydrochloride is an adenosine diphosphate (ADP) receptor inhibitor against platelet aggregation with IC50 of ~2 μM. Target: Adenosine diphosphate (ADP) Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Ticlopidine hydrochloride inhibits platelet aggregation with IC50 of ~2 μM in men. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. Its niche role as an alternative in those patients who do not tolerate Clopidogrel has now been superdeded by Ticagrelor and Prasugrel. The usual dose is 250 mg twice daily by the oral route. Ticlopidine hydrochloride, when orally administered to rats, results in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme.
benzyl N-(1,1,1,3,3,3-hexafluoropropan-2-ylidene)carbamate
ETHYL 2-(CHLOROMETHYL)-4-METHYLQUINOLINE-3-CARBOXYLATE HYDROCHLORIDE
3-(4-NITRO-PHENYL)-2-THIOXO-2,3-DIHYDRO-1H-QUINAZOLIN-4-ONE
6-CHLORO-2-(4-HYDROXY-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID
1-(8-methyl-6-oxo-[1,3]dioxolo[4,5-g]chromen-7-yl)pyrrole-2,5-dione
2,6-Diamino-4-(4-nitrophenyl)-4H-thiopyran-3,5-dicarbonitrile
2-chloro-1-methylpyridinium p-toluenesulfonate
C13H14ClNO3S (299.03828840000006)
2,6-diamino-4-(2-nitrophenyl)-4H-thiopyran-3,5-dicarbonitrile
6-CHLORO-2-(2-HYDROXY-PHENYL)-QUINOLINE-4-CARBOXYLIC ACID
N-PHENYL-1-NAPHTHYLAMINE HYDROBROMIDE,
C16H14BrN (299.03095440000004)
Pantothenic acid-13C3,15N hemicalcium
C9H17NO5.1/2Ca (299.03584920000003)
2,6-diamino-4-(3-nitrophenyl)-4H-thiopyran-3,5-dicarbonitrile
3-(p-Tolylsulfonylamino)-5-fluorouracil
C11H10FN3O4S (299.03760320000004)
N-acetyl-D-glucosamine 6-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-acetyl-alpha-D-glucosamine 1-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
N-acetyl-alpha-D-galactosamine 1-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
N-acetyl-D-galactosamine 6-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
N-acetyl-beta-D-glucosamine 6-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
an N-acetyl-alpha-D-hexosamine 1-phosphate
C8H14NO9P-2 (299.04061640000003)
N-acetyl-D-mannosamine 1-phosphate
C8H14NO9P-2 (299.04061640000003)
N-acetyl-alpha-D-glucosamine 6-phosphate
C8H14NO9P-2 (299.04061640000003)
9-Hydroxy-15-methyl-6,12,13-trioxa-3,5,15-triazatricyclo[7.3.2.11,4]pentadec-4-ene-2,7,11,14-tetrone
Ticlid
C14H15Cl2NS (299.03022100000004)
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
N-acetyl-D-mannosamine 6-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Tazobactam(1-)
A penicillinate anion that is the conjugate base of tazobactam, obtained by deprotonation of the carboxy group.
(4E)-2-[(E)-2-(4-chlorophenyl)ethenyl]-4-(furan-2-ylmethylidene)-1,3-oxazol-5-one
5-[(2-hydroxy-3-quinolinyl)methylene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
(4Z)-2-(4-chlorophenyl)-4-[(E)-3-(furan-2-yl)prop-2-enylidene]-1,3-oxazol-5-one
N-acetyl-D-hexosamine 1-phosphate(2-)
C8H14NO9P-2 (299.04061640000003)
(NZ)-N-[3-(3-nitrophenyl)-1,4-benzothiazin-2-ylidene]hydroxylamine
N-acetyl-D-glucosamine 6-phosphate(2-)
C8H14NO9P (299.04061640000003)
Dianion of N-acetyl-D-glucosamine 6-phosphate arising from deprotonation of both OH groups of the phosphate.
N-acetyl-alpha-D-glucosamine 1-phosphate(2-)
C8H14NO9P (299.04061640000003)
Dianion of N-acetyl-alpha-D-glucosamine 1-phosphate arising from deprotonation of the phosphate OH groups; major species at pH 7.3.
N-acetyl-D-mannosamine 6-phosphate(2-)
C8H14NO9P (299.04061640000003)
An organophosphate oxoanion resulting from the removal of both protons from the phosphate group of N-acetyl-D-mannosamine 6-phosphate.
N-acetyl-alpha-D-galactosamine 1-phosphate(2-)
C8H14NO9P (299.04061640000003)
An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of N-acetyl-alpha-D-galactosamine 1-phosphate; major species at pH 7.3.
N-acetyl-beta-D-glucosamine 6-phosphate(2-)
C8H14NO9P (299.04061640000003)
Dianion of N-acetyl-beta-D-glucosamine 6-phosphate.